Effects of teneligliptin on glycemic control and bone metabolic markers in diabetic patients undergoing hemodialysis

Effects of teneligliptin on glycemic control and bone metabolic markers in diabetic patients undergoing hemodialysis - Effects of teneligliptin on glucose and bone metabolism in diabetic patients undergoing hemodialysis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010780

Enrollment

Registered

2013-05-22

Start date

2013-05-27

Completion date

Unknown

Last updated

2025-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetic patients undergoing hemodialysis

Interventions

teneligliptin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria:

Exclusion criteria

Exclusion criteria: Patients with severe liver dysfunction (AST more than 100 or ALT more than 100 IU/L) Patients with malignancy under medical treatmennt Patients with untreated diabetic retinopathy Patients terated with insulin injection Patients disqualified by doctor for any reason

Design outcomes

Primary

Measure	Time frame
The improvement of glycemic control evaluated by area under the curve (AUC) using continuous glucose monitoring in the treatment with teneligliptin for 4 weeks	—

Secondary

Measure	Time frame
The changes of glyated albumin (GA) and bone metabolic markers in the treatment with teneligliptin for 4 weeks	—

Countries

Japan

Contacts

Public ContactKatsuhito Mori

Osaka City University Graduate School of Medicine 2nd department of internal medicine

ktmori@med.osaka-cu.ac.jp06-6645-3806

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Feb 4, 2026